IM-19 is under clinical development by Imunopharm Technology and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IM-19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IM-19 overview

IM-19 is under development for the treatment of relapsed or refractory B-cell acute  lymphoblastic leukemia, refractory systemic lupus erythematosus, B-cell acute lymphocytic leukemia (B-ALL), relapsed or refractory non-Hodgkin's lymphoma, diffuse large b-cell lymphoma, mantle cell lymphoma, IgA nephropathy and primary membranous nephropathy. The drug candidate is administered intravenously. It is developed based on chimeric antigen receptor (CAR) T-cell technology.
It was under development for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), Acute Lymphocytic Leukemia, follicular lymphoma and primary mediastinal b-cell lymphoma.

Imunopharm Technology overview

Imunopharm Technology (Imunopharm) is a clinical-stage biopharmaceutical company that develops innovative cell and gene therapies to treat serious diseases such as cancer and autoimmune disorders. The company’s pipeline products include IM19 targets diffuse large B-cell lymphoma, B-cell acute lymphoblastic leukemia, and mantle cell lymphoma; IM21 and INS21(InstanCART) for multiple myeloma. Its solid tumor products comprise IM83 targets hepatocellular carcinoma, IM18 for melanoma, IM92 treats gastric cancer and pancreatic cancer; and IM96 for carcinoma of the colon and rectum. The company utilizes its proprietary CAR-T technology platform to develop novel CAR-T therapeutics. Imunopharm is headquartered in Beijing, China.

For a complete picture of IM-19’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.